Rivfloza ® (nedosiran) injection 80 mg, 128 mg, or 160 mg is a prescription medicine used to lower urinary oxalate levels in children 9 years of age and older and adults with primary …

Rivfloza ®, or nedosiran, injection is an RNAi therapy indicated for the treatment of PH1 to lower urinary oxalate levels in pediatric and adult patients aged 9 years and older with relatively …

2023年10月2日 · Rivfloza is an LDHA-directed small interfering RNA medicine. Rivfloza is usually given as an injection under the skin (subcutaneously) once a month. Rivfloza became an FDA …

RIVFLOZA is indicated to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function,...

2023年10月3日 · 诺和诺德（NovoNordisk）今天宣布，美国FDA批准其RNAi疗法Rivfloza（nedosiran）注射液（80 mg、128 mg或160 mg），用于降低9岁及以上儿童和成 …

Rivfloza ® (nedosiran) injection 80 mg, 128 mg, or 160 mg is indicated to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) …

Rivfloza ® (nedosiran) injection 80 mg, 128 mg, or 160 mg is a prescription medicine used to lower urinary oxalate levels in children 9 years of age and older and adults with primary …

RIVFLOZA® is an LDHA-directed small interfering RNA indicated to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and …

Rivfloza ® (nedosiran) injection 80 mg, 128 mg, or 160 mg Rivfloza ® is indicated to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 …

2025年1月10日 · Overview: Rivfloza is used for primary hyperoxaluria type 1 (PH1) to help lower oxalate levels in urine (pee). Common side effects include redness, pain, bruising, or rash …